Literature DB >> 3372545

Studies on yellow fever vaccine. III--Dose response in volunteers.

S Lopes Ode1, S S Guimarães, R de Carvalho.   

Abstract

Standard and stabilized yellow fever (YF) vaccines were compared on the basis of the serological responses of human volunteers to varying doses of vaccine measured as pfu or LD50. The addition of stabilizer substances to bulk vaccine did not affect the immunogenicity and stabilized vaccine gave a consistently good performance. The vaccine fulfilled WHO recommendations in inducing 100% serological conversion in volunteers given about 200 pfu or 600 LD50.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3372545     DOI: 10.1016/0092-1157(88)90034-0

Source DB:  PubMed          Journal:  J Biol Stand        ISSN: 0092-1157


  11 in total

Review 1.  Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years.

Authors:  Eduardo Gotuzzo; Sergio Yactayo; Erika Córdova
Journal:  Am J Trop Med Hyg       Date:  2013-09       Impact factor: 2.345

2.  Immunogenicity of Fractional-Dose Vaccine during a Yellow Fever Outbreak - Final Report.

Authors:  Rebecca M Casey; Jennifer B Harris; Steve Ahuka-Mundeke; Meredith G Dixon; Gabriel M Kizito; Pierre M Nsele; Grace Umutesi; Janeen Laven; Olga Kosoy; Gilson Paluku; Abdou S Gueye; Terri B Hyde; Raimi Ewetola; Guylain K M Sheria; Jean-Jacques Muyembe-Tamfum; J Erin Staples
Journal:  N Engl J Med       Date:  2018-02-14       Impact factor: 91.245

Review 3.  Historical review of clinical vaccine studies at Oswaldo Cruz Institute and Oswaldo Cruz Foundation--technological development issues.

Authors:  Reinaldo de Menezes Martins; Cristina de Albuquerque Possas; Akira Homma
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-01-16       Impact factor: 2.743

4.  Subdoses of 17DD yellow fever vaccine elicit equivalent virological/immunological kinetics timeline.

Authors:  Ana Carolina Campi-Azevedo; Paula de Almeida Estevam; Jordana Grazziela Coelho-Dos-Reis; Vanessa Peruhype-Magalhães; Gabriela Villela-Rezende; Patrícia Flávia Quaresma; Maria de Lourdes Sousa Maia; Roberto Henrique Guedes Farias; Luiz Antonio Bastos Camacho; Marcos da Silva Freire; Ricardo Galler; Anna Maya Yoshida Yamamura; Luiz Fernando Carvalho Almeida; Sheila Maria Barbosa Lima; Rita Maria Ribeiro Nogueira; Gloria Regina Silva Sá; Darcy Akemi Hokama; Ricardo de Carvalho; Ricardo Aguiar Villanova Freire; Edson Pereira Filho; Maria da Luz Fernandes Leal; Akira Homma; Andréa Teixeira-Carvalho; Reinaldo Menezes Martins; Olindo Assis Martins-Filho
Journal:  BMC Infect Dis       Date:  2014-07-15       Impact factor: 3.090

5.  A qualitatively validated mathematical-computational model of the immune response to the yellow fever vaccine.

Authors:  Carla R B Bonin; Guilherme C Fernandes; Rodrigo W Dos Santos; Marcelo Lobosco
Journal:  BMC Immunol       Date:  2018-05-25       Impact factor: 3.615

6.  Duration of post-vaccination immunity to yellow fever in volunteers eight years after a dose-response study.

Authors:  Reinaldo de Menezes Martins; Maria de Lourdes S Maia; Sheila Maria Barbosa de Lima; Tatiana Guimarães de Noronha; Janaina Reis Xavier; Luiz Antonio Bastos Camacho; Elizabeth Maciel de Albuquerque; Roberto Henrique Guedes Farias; Thalita da Matta de Castro; Akira Homma
Journal:  Vaccine       Date:  2018-05-18       Impact factor: 3.641

7.  WHO Working Group on Technical Specifications for Manufacture and Evaluation of Yellow Fever Vaccines, Geneva, Switzerland, 13-14 May 2009.

Authors:  Morag Ferguson; Jinho Shin; Ivana Knezevic; Philip Minor; Alan Barrett
Journal:  Vaccine       Date:  2010-11-04       Impact factor: 3.641

8.  Randomized, double-blinded, controlled non-inferiority trials evaluating the immunogenicity and safety of fractional doses of Yellow Fever vaccines in Kenya and Uganda.

Authors:  Derick Kimathi; Aitana Juan; Philip Bejon; Rebecca F Grais; George M Warimwe
Journal:  Wellcome Open Res       Date:  2019-11-20

9.  17DD yellow fever vaccine: a double blind, randomized clinical trial of immunogenicity and safety on a dose-response study.

Authors:  Reinaldo M Martins; Maria de Lourdes S Maia; Roberto Henrique G Farias; Luiz Antonio B Camacho; Marcos S Freire; Ricardo Galler; Anna Maya Yoshida Yamamura; Luiz Fernando C Almeida; Sheila Maria B Lima; Rita Maria R Nogueira; Gloria Regina S Sá; Darcy A Hokama; Ricardo de Carvalho; Ricardo Aguiar V Freire; Edson Pereira Filho; Maria da Luz Fernandes Leal; Akira Homma
Journal:  Hum Vaccin Immunother       Date:  2013-01-30       Impact factor: 3.452

10.  Lessons Learned from Emergency Response Vaccination Efforts for Cholera, Typhoid, Yellow Fever, and Ebola.

Authors:  Jenny A Walldorf; Kashmira A Date; Nandini Sreenivasan; Jennifer B Harris; Terri B Hyde
Journal:  Emerg Infect Dis       Date:  2017-12       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.